Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Promis Neurosciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
PMN
Nasdaq
8731
https://www.promisneurosciences.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Promis Neurosciences Inc
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
- Apr 30th, 2024 11:00 am
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
- Apr 9th, 2024 11:00 am
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
- Apr 4th, 2024 11:00 am
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
- Apr 1st, 2024 8:15 pm
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
- Mar 11th, 2024 11:00 am
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
- Feb 22nd, 2024 12:00 pm
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
- Jan 22nd, 2024 12:00 pm
ProMIS Neurosciences Issues Letter to Shareholders
- Jan 8th, 2024 12:00 pm
ProMIS Neurosciences, Inc. Announces Leadership Transition
- Jan 3rd, 2024 12:00 pm
ProMIS Neurosciences Announces Publication on Novel Target for ALS
- Dec 20th, 2023 12:00 pm
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
- Nov 20th, 2023 12:00 pm
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
- Nov 14th, 2023 9:30 pm
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
- Sep 8th, 2023 11:00 am
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Sep 6th, 2023 4:18 pm
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
- Aug 21st, 2023 8:12 pm
ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
- Aug 14th, 2023 9:33 pm
ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline
- Jul 17th, 2023 11:00 am
ProMIS Announces Completion of Continuance
- Jul 14th, 2023 11:45 am
ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange
- Jul 10th, 2023 11:55 am
ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
- Jun 30th, 2023 12:00 pm
Scroll